Press releases

Ziccum har haft ett mycket produktivt kvartal, med avsevärda framsteg inom de tre fokusområdena: Partnering, Teknologiutveckling och Förstudien för mRA/LNP-plattformen. Ann Gidner, Ziccums nya VD som tillträdde i maj månad...

INTERIM REPORT Q3 2022: 1 JANUARY – 30 SEPTEMBER 2022. To read the digital Report, please click here: https://reports-en.ziccum.com/interim-report-q3-2022/start/ Significant events during Q3 (July-September) On July 19, Ziccum published the selected...

ZICCUM AB (publ) has generated proof of successful nebulization and drying of vaccine lipid nanoparticles (LNP) in its in-house mRNA project. This was carried out using LaminarPaceTM, the company’s ambient drying technology. LNP is the preferred...

Ziccum AB (publ) (‘Ziccum’) today announces that is has reopened its application process for CEPI’s Call for Proposals (CfP) from companies developing innovative technologies to improve vaccine thermostability. Ziccum will submit an...

Ziccum AB (publ) (‘Ziccum’) has today received readout results from the latest stage of an evaluation agreement study carried out with a leading pharmaceutical corporation (previously communicated on June 3, 2026) analyzing LaminarPace’s...

Following their agreed collaboration, Ziccum AB and the team from the ICP Institute of Computational Physics at the Zurich University of Applied Sciences’s School of Engineering (ZHAW) have now submitted an application to the Eurostars funding body...

Ziccum AB will be intensifying its partnering and networking dialogues at a series of leading pharma industry events throughout Europe this year. CEO Ann Gidner: “As we strengthen our connections with colleagues throughout the industry, we remain...

INTERIM REPORT Q2 2022: 1 JANUARY – 30 JUNE 2022. To read the digital Report click here: https://reports-en.ziccum.com/interim-report-q2-2022/ Significant events during Q2 (April-June) Significant events during Q1 (Jan-March) With a new CEO, the...

Ziccum AB has appointed a Scientific Director, as part of a major reorganisation aiming to facilitate and accelerate its new strategic focus on key projects and vaccine platforms. Ziccum Senior Formulation Specialist Fabrice Rose will assume the new role...

Ziccum AB, in partnership with the prestigious Zurich University of Applied Sciences, is applying for funding to Eurostars for a joint project developing the 3D modelling of LaminarPace, its unique room-temperature drying system that formulates vaccines...